2011 E-Update Number 8

Donate
In this Issue
FDA Approves Afinitor
Survivor Stories Welcome
Run with Team CFCF
Advertisement from our Sponsor
NVS logo
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation
Follow us on Twitter!
 
Join us on Facebook!
 
Visit us on Navigating Cancer! 
Survivor Stories
Mark Zwanziger 
(submitted 5/2/11)
  
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients.

Read our newest survivor stories:
Join Us for a Cure
seatle to portland 08

Make a difference and get involved with CFCF!  Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events!
Quick Links...
Give hope and a future to  neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible.  We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible. 

Donate

To learn more, view CFCF's:
Audited Financial Statements
IRS Form 990

Caring for Carcinoid Foundation
198 Tremont Street, Box 456
Boston, MA 02116
617.948.2514
www.caringforcarcinoid.org
BBB Accredited Charity
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report.
FDA Approves Afinitor for Pancreatic Neuroendocrine Tumors

Approval

Last week, the Caring for Carcinoid Foundation was proud to break the news  that Afinitor received FDA approval for patients with pancreatic neuroendocrine tumors. Specifically, Afinitor tablets have been approved to treat patients with progressive pancreatic neuroendocrine tumors that are unresectable, locally advanced or metastatic.

 

Afinitor's approval is an important advance in treating pancreatic neuroendocrine tumor patients.  It is the first FDA approved therapy for these patients since 1982.

 

Read more about Afinitor's FDA review and approval. Any patients considering this or any other potential treatment should consult with a physician well-versed in treating neuroendocrine tumor patients. Experienced clinicians are necessary to understand the best timing and duration of therapy with Afinitor or other potential treatments. Please consult CFCF's Doctor Database or call 617-948-2514 for help finding an experienced clinician.

CFCF Welcomes Your Survivor Stories

Sunflower


We welcome your Survivor Story submissions.

 

Survivor Stories provide an opportunity for patients to support each other through their personal experiences using their unique voices. The stories reflect remarkable courage and determination, providing hope for patients and caregivers alike.  They also help motivate your fellow patients to action and serve as a forum to connect.

 

Check out the featured stories on our website and in this week's E-update, and consider sharing your story with our community today!

Run for a Cure With Team CFCF
run

2011 has been a great year for Team CFCF athletes! We have met passionate runners and walkers from Texas to California to Tennessee.

 

Won't you join in the fun?

 

We still have charity spots available for the Bank of America Chicago Marathon on October 9 and the Marine Corps Marathon on October 30 in Washington, D.C. These are two of the premier races in America, featuring beautiful urban landscapes and crowds of enthusiastic supporters. General registration is now closed, so don't miss out on this great opportunity to grab one of our remaining charity slots. With both marathons taking place in October, you still have plenty of time to get into marathon shape!

 

Contact Frances [email protected] for details on registration. Hurry - these are very popular races! 

 

We'll see you at the finish line!

Advertisement from our Sponsor

 iWalk for Carcinoid  FDA MedWatch Full Prescribing Information